GeoVax has successfully entered Phase II trials for its AIDS vaccines that work against multiple HIV-1 proteins, to protect against the development of AIDS in HIV-infected humans. VGXI provides DNA Plasmids for these clinical trials.
In pursuit of the world's first Herpes prophalaxis
Following his research that led to a successful HPV vaccine, Prof. Ian Frazer is leading Coridon into Phase I trials for a combined prophylactic and therapeutic HSV-2 vaccine. VGXI successfully scaled a fermentation process to stay on schedule.
Pioneering in DNA vaccines with innovative drug delivery that increases cell membrane permeability for greater therapeutic absorption by as much as 1000x. Inovio relies on VGXI for highly concentrated DNA Plasmids.